|Day Low/High||66.53 / 67.62|
|52 Wk Low/High||42.48 / 67.21|
The Medical Technology Stock Letter's top pick rose 357% in 2019.
How to prepare your portfolio and be opportunistic in the face of this geopolitical instability.
Let's review 2019 performance of RMPIA in relation to stock indexes and see what's ahead.
The drugmaker's shares are up about 50% since last July and could use a rest, but are likely to move higher longer term.
Bristol-Myers Squibb, Amgen and Abbott Labs all recently raised their dividends and should prosper amid the aging population.
The impeachment and trial of President Trump has nothing to do with the price to earnings ratio of Bristol-Myers or any other stock for that matter.
Biotech is on fire right now, but these 3 stocks 'sleeper' stocks aren't yet overbought.
We are playing defense as we see some downward pressure on oil and healthcare weakness.
There may be sideways action in the drugmaker's shares in the near term, but a strong move higher is possible down the road.
We're seeing lots of companies snapping up their peers, and the market is applauding.
Also, Fed Chairman Powell says there are no plans for a U.S. digital currency (for now), plus Tesla's electric pickup.
The market is throwing a Halloween sale right now that it doesn't need to throw, and that's an opportunity.
I do think that this Fed Chair has learned to be cautious, in reflection of the policy errors made in late 2018.
Traders can learn from watching, as well as doing, and with the FOMC meeting landing, now's best time to practice the former.
These stocks are priced for total imperfection. That's just what you want.
The stocks of many companies anticipated a more stringent series of tariffs and we didn't get them.
The price of EL has corrected lower, and if its quarterly report or guidance is better than expected, we should the uptrend resume.
Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.
A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.
The aging population is creating a massive tailwind for companies that provide cutting-edge health care.
TheStreet's quants like the stock. What do the charts say?
Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.